It is made available under a CC-BY-NC-ND 4.0 International license.

1 **Influence of ethnicity and consanguinity on the genetic architecture of Hypertrophic** 2 **Cardiomyopathy: insights from an understudied population** 3 **Keywords:** Egyptian Collaborative Cardiac Genomics Project, homozygosity, NGS 4 5 Mona Allouba,^{1,2,11,*} Roddy Walsh,^{2,3,11} Alaa Afify,¹ Mohammed Hosny,^{1,4} Sarah Halawa,¹ Aya 6 Galal,¹ Mariam Fathy,¹ Pantazis I. Theotokis,² Ahmed Boraey,¹ Amany Ellithy,¹ Rachel 7 Buchan,^{2,5} Risha Govind,^{2,5,6,7} Nicola Whiffin,^{2,5,8,} Shehab Anwer,¹ Ahmed ElGuindy,¹ James 8 S. Ware, ^{2,5,9,12} Paul J.R. Barton, ^{2,5,9,12} Yasmine Aguib, ^{1,2,12*}, Magdi Yacoub, ^{1,2,10,12*} 9 10 ¹ Aswan Heart Centre, Aswan, Magdi Yacoub Heart Foundation, Egypt ² National Heart and Lung Institute, Imperial College London, London, United Kingdom ³ Department of Experimental Cardiology, Amsterdam UMC, the Netherlands 13 ⁴ Cardiology Department, Kasr Al Aini Medical School, Cairo University 14 ⁵ Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, 15 London, United Kingdom 16 ⁶ Present affiliation: Institute of Psychiatry, Psychology and Neuroscience, King's College 17 London, London, United Kingdom 18 ⁷ Present affiliation: National Institute for Health Research (NIHR) Biomedical Research 19 Centre, South London and Maudsley NHS Foundation Trust and King's College London, 20 London, United Kingdom 8 21 ⁸ Present affiliation: Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 22 7BN, United Kingdom 23 ⁹ MRC London Institute of Medical Sciences, Imperial College London, London, United 24 Kingdom 25 ¹⁰ Harefield Heart Science Centre, United Kingdom 26 27 28 29 30 31 32 33 34 35 36 37

¹¹ These authors contributed equally

¹² Senior author

^{*}**โดวนะวรเฉวกฝุ่อกCe**p<u>ons กองอโยรปลอเพิ่มเทลรไกดบอลเพอสเหย่อ ญิ ตอออย่ะเจอพวกสารหอาดางbาดิ และลอย่าลูโเสร clinical practice.</u>

Abstract

 Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition characterized by phenotypic heterogeneity that could partly be explained by the variability in genetic variants contributing to disease. Accurate interpretation of these variants constitutes a major challenge for diagnosis and implementing precision medicine, especially in understudied populations. Here, we leverage ancestry-matched Egyptian patients (n=514) and deeply-phenotyped controls (n=400) to accurately define the genetic architecture of HCM. We also compare HCM variation between Egyptian and predominantly European patients to identify genetic features unique to consanguineous populations in Middle East and North Africa (MENA), which are likely to represent important contributors to disease. We report a higher prevalence of 49 homozygous variants in Egyptian patients (4.1% vs 0.1%, p-value= $2x10^{-7}$), with variants in the minor HCM genes *MYL2*, *MYL3* and *CSRP3* more likely to present in homozygosity than the major genes (*MYH7*, *MYBPC3*), suggesting that these variants are less penetrant in heterozygosity. Biallelic variants in the recessive HCM gene *TRIM63* were detected in 2.1% of patients (5-fold greater than European patients), highlighting the importance of recessive inheritance/genes in consanguineous populations. Finally, significantly fewer rare variants detected in Egyptian HCM patients could be classified as (likely) pathogenic compared to 56 Europeans (40.8% vs. 61.6%, p-value=1.6x10⁻⁵) due to the underrepresentation of MENA populations in current HCM databases. This proportion increased to 53.8% after incorporating methods that compare variant frequencies between Egyptian patients and controls. Together, our findings demonstrate that studying consanguineous populations reveals novel insights with relevance to genetic testing and our understanding of the genetic architecture of HCM.

-
-
-
-

Introduction

 Hypertrophic cardiomyopathy (HCM [MIM: 192600] is a common inherited cardiac condition 68 affecting at least 1:500 in the general population 1.2 . It is defined by left ventricular hypertrophy (LVH) in the absence of other identifiable cardiac or systemic causes. Since its first description in 1958, HCM has been considered as a highly heterogenous disease with regards to mode 71 of inheritance, phenotype and genotype $3-5$. The genetic etiology of HCM is largely attributed to variation in genes that encode components of the contractile apparatus (sarcomere) in cardiac muscle cells.

 Large HCM datasets from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) and other diverse ancestral HCM populations have provided strong evidence supporting disease-77 associated, long-term adverse clinical outcomes, including mortality $6-11$. With respect to genotype, SHaRe demonstrated that patients with pathogenic sarcomere variants had an 79 earlier onset of disease and were at a higher risk of developing adverse clinical outcomes . Given the interplay between genetics and disease progression, these patients may benefit from effective treatments that delay or prevent HCM-related complications provided these 82 pathogenic variants are well characterized $10,12$. Although immense progress has been made in elucidating the genetic determinants of HCM, much remains to be explored including genetic-, environmental- and epigenetic factors influencing disease penetrance and expressivity. Also, the rapid integration of genetic testing into everyday clinical practice has resulted in the identification of a large number of variants of uncertain significance, which 87 cannot be acted upon clinically^{10,13,14}. This issue is more evident in underrepresented populations, who are more likely to receive inconclusive genetic testing results, compared to 89 well-studied European-ancestry HCM patients . Therefore, extending genomic research to diverse ancestral populations will not only reduce health disparities as we move towards precision-based HCM patient management but may also enhance variant interpretation for

 diagnosis, and provide novel genetic and mechanistic insights into the disease. For example, we have recently reported the identification of a new class of HCM pathogenic variants in *MYH7*, which was enriched in Egyptian patients over ancestry-matched controls and absent 95 from large-scale HCM patients of predominantly European ancestry $16-18$.

 The aim of this study is to define the genetic architecture of HCM in the previously 98 understudied Egyptian population that is known to have a high rate of consanguinity $19,20$. This study provides, to our knowledge, the largest and most comprehensive analysis of HCM in the Middle East and North Africa (MENA) region to date. We leverage a prospective Egyptian HCM cohort and an ancestry-matched, Egyptian healthy volunteer control cohort with comprehensive cardiovascular phenotyping, to define the genetic architecture of HCM in Egypt. In addition, we compare genetic data between Egyptian and well-characterized patients of predominantly European ancestry to identify genetic features unique to consanguineous populations of MENA ancestry which are likely to be important contributors of HCM.

Methods

Study population

Egypt HCM cohort

 A prospective cohort of unrelated HCM patients (n=514) was recruited to the Aswan Heart Centre (AHC), Egypt as part of the Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project and the National HCM Registry. This cohort is hereafter referred to as Egypt HCM. Clinical diagnosis of HCM was confirmed by echocardiography and/or Cardiac Magnetic Resonance (CMR) imaging.

UK HCM cohort

 A prospective cohort of HCM patients of predominantly European ancestry (n=684) was recruited by the NIHR Cardiovascular Biomedical Research Unit at the Royal Brompton

119 Hospital (RBH), London . This cohort is hereafter referred to as UK HCM. HCM diagnosis was confirmed with CMR.

Egypt control cohort

 Egyptian healthy volunteers (n=400) were recruited from across the country as part of the Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project aiming to study local genetic 125 variation in 1000 healthy individuals . All volunteers underwent detailed cardiovascular phenotyping, including clinical examination, 12-lead electrocardiogram, and CMR to confirm absence of CVD. This cohort is hereafter referred to as Egypt control.

UK control cohort

 UK healthy volunteers (n=1,054) of predominantly European ancestry were recruited 131 prospectively via advertisement for the UK Digital Heart Project at Imperial College London²². All volunteers, denoted hereafter as UK controls, underwent CMR to confirm the absence of cardiac disease.

 Participants from all four cohorts provided informed consent and were approved by their local research ethics committees.

Gene selection:

 DNA samples from the above-mentioned case and control cohorts were sequenced on Illumina platforms (Miseq, Nextseq or Hiseq) and a subset of these on Life Technologies 140 SOLiD 5500xl using cardiac gene panels including the TruSight Cardio Sequencing kit 23 . The number of HCM patients and controls from the Egypt and UK cohorts analyzed for each gene are depicted in Supplementary Table 1. Thirteen validated autosomal dominant HCM genes, including sarcomere-encoding (*ACTC1* (MIM: 102540), *MYBPC3* (MIM: 600958), *MYH7* (MIM:160760*)*, *MYL2* (MIM: 160781), *MYL3* (MIM: 160790), *TNNC1* (MIM: 191040), *TNNI3* (MIM: 191044), *TNNT2* (MIM: 191045) and *TPM1* (MIM: 191010)) and non-sarcomere-encoding genes (*PLN* (MIM: 172405), *ACTN2* (MIM: 102573), *CSRP3* (MIM: 600824), *JPH2*

147 (MIM: 605267)) were analyzed $21,24,25$. Genes, which have been previously shown to account 148 for less than 5% of HCM cases were defined in this work as "minor" genes ¹⁸. MYH7 and *MYBPC3* were defined here as "major" genes as they account for over 70% of identified 150 pathogenic variants in HCM 26 . Separately, biallelic variants in the recently implicated recessive HCM gene *TRIM63* (MIM: 606131) were evaluated. Some genes recently identified as rarer causes of HCM (*ALPK3* (MIM: 617608), *FHOD3* (MIM: 609691, *FLNC* (MIM: 102565) were not included on the gene panels used in this study.

Rare variant filtering and classification

 Rare variants in validated HCM genes were defined as having a filtering allele frequency (FAF) of ≤ 4x10-5 in gnomAD (v2.1.1) based on the statistical framework proposed by Whiffin *et al.,* 158 2017²⁷. Variants were annotated by CardioClassifier based on rules defined by the American College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG-AMP) as Pathogenic (P), Likely Pathogenic (LP) and Uncertain Significance (VUS) (full details in 161 Supplementary Methods) 28,29 . Detailed lists of all rare variants observed in the Egyptian and UK HCM and control cohorts are provided in Supplementary Tables 2-5.

Comparison of the genetic landscape of HCM between Egypt and UK HCM cohorts

 First, the genetic architecture of the HCM in the Egyptian population was assessed by comparing the frequency of rare variation in validated HCM genes between ancestry-matched patients and controls. Second, the genetic landscape of HCM was compared between the Egypt and UK HCM cohorts using their respective population-matched controls. For each gene, the excess of rare variants in the Egypt HCM cohort over the Egypt control cohort was 170 compared with the excess of rare variants in the UK cohort over UK controls (Egypt HCM_{Control} 171 excess vs. UK HCM_{Control} excess). Third, the proportion of genotype-positive patients (i.e., 172 those carrying rare variants) attributable to each HCM gene was compared between the Egypt and UK HCM cohorts.

Comparison of the proportion of clinically actionable variants between the Egypt and UK HCM cohorts

 The proportion of clinically actionable variants (i.e., P and LP) was evaluated in the Egypt HCM cohort by dividing the number of patients with P/LP variants by the total number of patients with rare variants in validated HCM genes. For patients with multiple hits (refer to Supplementary Tables 6 and 7), the variant with the highest pathogenicity was prioritized (i.e., P then LP then VUS). The proportion of clinically actionable variants was then compared 181 between the Egypt and UK HCM cohorts.

Application of the new Etiological Fraction (EF)-based American College of Medical

Genetics and Genomics/Association or Molecular Pathology (ACMG-AMP) rule on rare

MYH7 **missense variants**

 The effect of the recently proposed EF-based ACMG/AMP rules by Walsh *et al.,* 2019 on the yield of actionable *MYH7* missense variants (i.e. P and LP) identified in the Egypt HCM cohort 188 was assessed 13 .

 First, we evaluated whether the regional distributions of pathogenic and benign variation in *MYH7*, previously observed in European individuals, is also observed in Egyptians. The frequency of rare missense *MYH7* variants in the predefined patient-enriched HCM cluster 192 (residues: 167-931) was calculated ¹³. The distribution of rare missense *MYH7* variants in the Egypt HCM and control cohorts and was visualized using the TrackViewer package (v 1.22.1) in R statistical environment (v 3.6.3). This was further compared with the previously published cohort of >6,000 HCM patients from Partners Laboratory of Molecular Medicine and Oxford 196 Medical Genetics Laboratory (denoted here as LMM/OMGL)¹⁸. Second, the odds ratio (OR) and etiological fraction (EF) (EF = (OR-1)/OR) for this cluster were calculated using the Egypt control cohort as the reference control population.

 MYH7 missense variants were classified as per the adopted new EF-based PM1_strong rule, which is activated if these variants are located in a protein region with EF≥0.95

202 **Results**

203 **Cohort characteristics**

204 The Egypt HCM cohort comprised 514 patients (67% male, 33% female; full details in 205 Supplementary Table 8). Consanguinity was reported in 28.4% of Egyptian patients. Notably,

- 206 UK patients (n=684) were ca. 20 years older (mean onset age 55.5+15.5 years vs. 34.7 + 17.4
- 207 years, p-value< $2.2x10^{-16}$), presented with less severe hypertrophy (LVMWT: 18.9+4.4mm vs.
- 208 $23.6+7$ mm, p-value=4.9x10⁻¹⁵) and showed a lower incidence of left ventricular outflow tract
- 209 obstruction (LVOTO) (24%) compared to Egyptian patients (36% vs. 73%, p-value< $2.2x10^{-16}$).
- 210 A summary of the demographic- and cardiac characteristics of the Egypt and UK HCM cohorts
- 211 with available data is outlined in Table 1.
- 212

213 **Table 1: Demographic and cardiac characteristics of Egypt and UK HCM cohorts**

^TConsanguinity (self-reported) was defined as first-cousin marriage. FH: Family History, SCD: Sudden
215 Cardiac Death, LVMWT: Left Ventricular Maximal Wall Thickness, LVOTO: Left Ventricular Outflow 215 Cardiac Death, LVMWT: Left Ventricular Maximal Wall Thickness, LVOTO: Left Ventricular Outflow 216 Tract Obstruction, LVEF: Left Ventricular Ejection Fraction, ICD: Implantable Cardioverter Defibrillator. 217 **LVMWT and LVEF were measured in the Egypt HCM and UK HCM cohorts by echocardiography and

- 218 CMR, respectively.
- 219

220 **Differences in the genetic architecture of HCM between Egyptian- and UK patients**

- 221 In order to evaluate the genetic architecture of HCM in Egypt, we compared the burden of rare
- 222 variation (gnomAD_{popmax} FAF <4x10⁻⁵) in validated HCM genes between Egyptian patients and

 controls (Figure 1A, left). The inclusion of ancestry-matched controls into this analysis enabled us to address the potential bias introduced by defining rare variants using gnomAD, which has minimal representation from the MENA region (Supplementary Figure 1).

227 In addition, we compared the genetic landscape of HCM between the Egypt and UK HCM cohorts (using their respective population-matched controls), to directly compare the excess 229 burden of rare variants in HCM-associated genes in each cohort (labelled as Egypt HCM_{Control} 230 excess and UK HCM_{Control} excess) (Figure 1A, right). A higher overall excess burden of rare variation was observed in the Egypt HCM cohort compared to UK HCM (52.7% vs. 32.0%) (Figure 1A), with 1.6-fold more Egyptian patients carrying rare variants compared to UK HCM (Figure 1B). We then performed a secondary analysis comparing the proportion of genotype- positive patients (i.e., those carrying rare variants) attributable to each HCM gene between the Egypt and UK HCM cohorts (Figure 1C).

 As expected, rare variants in both *MYH7* and *MYBPC3* accounted for the majority of rare variation in both the Egypt and UK HCM cohorts (Table 2). *MYBPC3* non-truncating variants and *PLN* variants accounted for a higher proportion of genotype-positive patients in the UK HCM cohort compared to Egyptian patients (*MYBPC3*: 26.9% vs. 13.7% and *PLN*: 0.92% vs. 0%) (Table 2). In contrast, *MYH7* truncating variants accounted for a higher proportion of genotype-positive patients in the Egypt HCM cohort, which is explained by the recurrent variant c.5769delG [p.Ser1924AlafsTer9]. This variant was present in 3.3% of Egypt HCM patients and we recently showed that it causes HCM by introducing a distal premature 245 termination codon, which escapes nonsense mediated decay resulting in the expression of an 246 abnormal protein¹⁶. Several recurrent truncating variants in *MYBPC3* were also detected, with two of these (c.1516delG [p.Asp506ThrfsTer7] (0.97%, n=5) and c.534_541delGGCCGGCG [p.Ala179GlnfsTer59] (1.36%, n=7)) likely to be Egyptian/North African specific founder 249 variants. *MYBPC3* founder variants have similarly been reported in numerous regions ³⁰.

 Due to the limited number of observed variants, HCM genes encoding components of the thin filament (*ACTC1*, *TNNC1*, *TNNI3*, *TNNT2* and *TPM1*) and myosin light chain (MLC: *MYL2* and *MYL3*) were combined into groups based on their similar function. While rare variation in thin filament genes accounted for a relatively higher proportion of genotype-positive patients in the UK HCM cohort compared to Egypt HCM (12.3% vs. 6.6%), non-truncating variants in MLC genes accounted for a higher proportion of genotype-positive patients in the Egypt HCM cohort (9.96% vs. 2.28%) (Table 2).

 Six distinct variants were identified in each of *MYL2* (5 missense and 1 splice site) and *MYL3* (6 missense) (Supplementary Table 2)*.* Of these, three *MYL2* variants were recurrently observed in Egyptian patients (c.173G>A [p.Arg58Gln] (n=2,0.39%), c.450G>T [p.Leu150Phe] (n=3,0.58%) and c.278C>T [p.Ala93Val] (n=5, 0.97%)). In *MYL3* 3/6 missense variants observed in Egyptian patients were also recurrent (c.460C>T [p.Arg154Cys] (n=2,0.39%), c.518T>C [p.Met173Thr] (n=4,0.78%) and c.508G>C [p.Glu170Gln] (n=6,1.17%)). With the exception of the known pathogenic *MYL2* p.Arg58Gln variant, these recurrent variants were absent from both the UK HCM cohort and LMM/OMGL HCM cohorts. Also, the *MYL2* variant p.Leu150Phe has not been previously reported whereas the other ten MLC variants are currently classified as VUS in ClinVar.

 For the non-sarcomeric HCM genes, rare variants in both *CSRP3* (truncating and non- truncating) and *JPH2* (non-truncating) showed a nominal enrichment in the genotype-positive Egypt HCM cohort compared to UK HCM (Table 2).

 To explore why variants in some minor HCM genes (MLC, *CSRP3* and *JPH2*) seem to be more prevalent in the Egypt HCM cohort compared to UK HCM , we then examined the effect of consanguinity, and the frequency of homozygous variants, on this cohort.

It is made available under a CC-BY-NC-ND 4.0 International license.

 Figure 1: Enrichment of rare variation in HCM minor genes (MLC, *CSRP3 & JPH2***) in the Egypt HCM cohort vs. UK HCM. A)** The overall frequency of rare variants (gnomAD_{popmax} FAF <4x10⁻⁵) in 13
281 validated HCM genes was compared between Egypt and UK HCM patients and controls. A 1.6 fold validated HCM genes was compared between Egypt and UK HCM patients and controls. A 1.6 fold greater excess burden (i.e. total case frequency – total control frequency) was observed in the Egypt HCM cohort, which should be accounted for with the direct gene comparisons (B). **B)** Population-284 matched patients vs. control comparison (Egypt HCM_{Control} excess and UK HCM_{Control} excess) of genetic variation between Egypt and UK cohorts for each HCM gene/gene class. C) Comparison of the proportion of genotype-positive patients (i.e., those carrying rare variants) per HCM gene confirms the enrichment of rare variants in the HCM minor genes MLC (*MYL2* & *MYL3*), *CSRP3* and *JPH2* in Egyptians (as observed in Figure B). Truncating and non-truncating variants (Figures A & B) are shown in red and grey, respectively. *Thin filament: ACTC1, TNNC1, TNNI3, TNNT2, TPM1.*

It is made available under a CC-BY-NC-ND 4.0 International license.

311 **Table 2: Comparison of population-matched patient versus control excess frequencies (left) and**

312 **the proportion of genotype-positive patients between Egypt HCM and UK HCM cohorts (right)** 313 **for sarcomeric- and other validated HCM genes**

Comparison of the excess of rare (FAF<4x10-5) variation in HCM patients over controls for Egypt and UK cohorts, grouped by gene/gene class and variant class (left). Note – the overall case excess across the validated HCM genes/gene classes is 1.6 times greater in the Egypt cohort (Figure 1A), therefore any comparisons for specific genes or gene classes between Egypt and UK cohorts should take this into account. The proportion of genotype-positive (i.e., those with rare variants) Egypt HCM and UK HCM patients per HCM gene is shown (left). RV: rare variants; G+: genotype-positive; prop: proportion.

- 314
- 315

316 **Higher burden of homozygous variants in the Egypt HCM cohort compared to UK HCM**

- 317 In the Egypt HCM cohort, 28% of patients reported to have consanguineous parents. This
- 318 prompted us to evaluate the frequency of homozygous variants, both for rare variants
- 319 (FAF_{popmax} $\leq 4.0x10^{-5}$) and for low frequency variants sufficiently rare to cause biallelic disease
- 320 (FAF_{popmax} \leq 0.00126)²⁷. The yield of homozygous variants was then compared with the UK
- 321 cohort.
- 322 As expected, homozygous variants were significantly more common in Egyptian patients
- 323 compared to UK, for both the rare $(4.1\%$ (n=21) vs. 0.1% (n=1), p=2x10⁻⁷) and low frequency
- 324 (2.1% (n=11) vs. 0%, p=8.5x10⁻⁵) variants. Table 3 summarizes the homozygous variants
- 325 observed in Egyptian patients. Homozygous variants in these genes were not observed in

 either the Egypt or UK control cohorts. Among Egypt HCM patients carrying homozygous variants, 31.3% reported not having consanguineous parents (i.e. first cousins), which may indicate an underreporting of consanguinity or more distantly related patients.

 Two Egyptian patients presented with homozygous *MYBPC3* truncating variants (c.1558G>T [p.Glu520Ter] and c.1227-2A>G). Truncating variants in *MYBPC3* are known to lead to 332 severe, early-onset disease when expressed in homozygosity . The patient carrying the nonsense variant p.Glu520Ter was indeed diagnosed with HCM at birth and died suddenly before adolescence. In contrast, the patient carrying the c.1227-2A>G splice variant in homozygosity presented with HCM in adulthood, although at a younger age and with more severe hypertrophy (LVMWT: 27mm vs. 20mm) than the patient with the same variant in the heterozygous state. Accordingly, this splice acceptor variant is predicted (by SpliceAI) to result in an exon extension of 33 intronic bases into the *MYBPC3* transcript, which suggests that the variant maintains the open reading frame and may therefore function as an inframe insertion (Supplementary Figure 2).

 Notably, homozygous variants were particularly enriched in three minor HCM genes (i.e. those previously shown to account for less than 5% of HCM patients each in European populations) 344 - *CSRP3* and the MLC genes *MYL2* and *MYL3*¹⁸ (Table 3). Therefore, we sought to compare the relative contribution of homozygous variants across the HCM genes. The proportion of 346 rare homozygous variants was consistent across the major HCM genes, with 5-7% of variants being homozygous in *MYH7*, *MYBPC3* and the thin filament genes (Table 4 and Figure 2). This proportion could be regarded as a background homozygosity rate for dominant HCM genes caused by the level of consanguinity present in the Egyptian population. In contrast the MLC and *CSRP3* genes showed a substantially higher proportion of homozygous variants (25.6% and 33.3%, respectively). It is worth mentioning that the increase in frequency of MLC homozygous variants from 14.3% (using the rare frequency threshold) to 25.6% (using the biallelic frequency threshold) was largely due to a recurrently observed low-frequency

It is made available under a CC-BY-NC-ND 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.09.22280408;](https://doi.org/10.1101/2022.10.09.22280408) this version posted October 10, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

354 (gnomAD_{popmax} FAF=4.4x10⁻⁵) *MYL3* variant c.530A>G [p.Glu177Gly] in the Egyptian cohort (0.78%,n=4).

 These findings suggest that, unlike the major HCM genes, rare variants in these minor genes may be generally less penetrant in the heterozygous state. Evidence for an additive, rather than a true recessive, model is supported by the fact that heterozygous variants in these genes are also enriched in Egyptian patients compared to controls and that the vast majority of previously reported pathogenic CSRP3 and missense MLC variants have been associated with autosomal dominant HCM. Taken together, these findings explain the relatively higher proportion of rare variants in MLC and CSRP3 genes observed in Egyptian patients compared to UK (Figure 1), with high consanguinity rates enabling variants to occur in a more penetrant homozygous state.

366 **Table 3: Details of homozygous variants identified in the Egypt HCM cohort (n=514) compared to Egypt controls (n=400)**

A) Summary of Egyptian variants that are sufficiently rare (gnomAD FAF_{popmax}≤4x10⁻⁵) to cause mono allelic disease. B) Additional variants that are sufficiently rare (gnomAD FAFpopmax≤0.00126) to cause biallelic disease are also shown. *****The *MYH7* variant c.5769delG was caused by a nucleotide deletion that was predicted to ultimately give rise to a near full-length protein (i.e., only 4 AAs shorter than the wildtype). The control frequency represents heterozygous counts (no homozygous variants were identified). **‡**This variant is unlikely to be pathogenic as it co-occurred with the pathogenic *MYH7* variant p.Arg870His in the HCM patient (also, it's allele frequency in gnomAD-Ashkenazi Jewish population is 0.007215).

It is made available under a CC-BY-NC-ND 4.0 International license.

367

368
369

369 **Table 4: Relative contribution of homozygous variants for validated autosomal dominant HCM** 370 **genes**

	Variants with gnomAD $FAFpopmax \leq 4 \times 10^{-5}$		Additional variants with gnomAD FAF _{popmax} ≤0.00126)		Total hom
Gene/Gene groups	Total no. of patients	Hom case freq(count)	Total no. of patients	Hom case freq(count)	freq (count/total)
MYH7	99	6.1% (6)	5	0%	5.8% (6/104)
MYBPC3	85	5.9% (5)	45	8.9% (4)	6.9% (9/130)
CSRP3	15	33.3% (5)	$\mathbf{0}$	0%	33.3% (5/15)
Myosin light chain	28	14.3% (4)	11	54.5% (6)	25.6% (10/39)
Thin filament	18	5.6% (1)	8	0%	3.8% (1/26)
ACTN ₂	12	0%	8	0%	0% (0/20)
JPH ₂	14	0%	4	25% (1)	5.6% (1/18)
PLN	0	0%	0	0%	0%

371 For genes with an excess burden of rare variants in Egypt HCM patients vs. UK (Table 2). The relative 372 contribution of rare (gnomAD FAF $_{\text{popmax}} \leq 4 \times 10^{-5}$) homozygous variants under dominant HCM model (left) 373 as well as of additional variants under recessive inheritance model (gnomAD FAF_{popmax}≤0.00126) (right) 374 are shown. MLC: *MYL2, MYL3*. Thin filament: *ACTC1, TNNC1, TNNI3, TNNT2, TPM1*.

are shown. MLC: MYL2, MYL3. Thin filament: *ACTC1, TNNC1, TNNI3, TNNT2, TPM1.* 375

376

377

378 **Figure 2: Comparison of the rate of homozygosity across the analyzed dominant HCM genes***.*

379 MLC- (*MYL2*, *MYL3*) and *CSRP3* genes showed a markedly higher rate of homozygosity compared to 380 major HCM genes (*MYBPC3*, *MYH7*) and thin filament genes (*ACTC1*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*).

A significantly higher proportion of VUSs is observed in the Egypt HCM cohort compared to UK HCM

 In contrast to MENA populations, European HCM patients have been extensively studied over the past decades. As a result, they are more likely to carry a disease-causing variant that has been previously well-characterized. Therefore, we hypothesize that in patients with rare variants in validated HCM genes, Egyptians have a higher proportion of VUSs compared to the UK HCM cohort.

 The proportion of patients with rare variants in HCM genes was 46.7% (n=240) and 28.9% (n=198) in the Egypt and UK HCM cohorts, respectively. As expected, the proportion of VUSs was significantly higher in the Egypt HCM cohort compared to UK (59.2% vs. 38.4%, p-392 value=1.6 $x10^{-5}$), which highlights the challenge in interpreting variants in understudied populations (Figure 3).

 Figure 3: Higher proportion of Variants of Uncertain Significance (VUSs) is observed in (A) Egyptian patients compared to (B) UK. For patients with rare variants in validated HCM genes, the 398 distribution of rare variants by variant classification (pathogenic (P), Likely Pathogenic (LP) and VUSs)
399 is shown. For patients with multiple hits (Supplementary Tables 6 and 7) the variant with the highest is shown. For patients with multiple hits (Supplementary Tables and 7) the variant with the highest pathogenicity was prioritized (i.e., P then LP then VUS). The proportion of VUSs was significantly higher 401 in Egypt HCM patients vs. UK (59.2% vs. 38.4%, p-value=1.6x10⁻⁵).

It is made available under a CC-BY-NC-ND 4.0 International license.

Analysis of HCM rare variation in the ancestry-matched Egyptian case-control cohort increases the proportion of clinically actionable variants

 The availability of genetic data from a deeply-phenotyped control cohort of 400 Egyptians as well as cohort-level analysis of the HCM patients described here enabled us to re-evaluate the classification of identified VUSs in patients by adopting 3 approaches. First, we examined 408 whether these VUSs were prevalent among our control cohort (i.e. $n\geq 2$; MAF ≥ 0.0025), which would increase the likelihood of them being likely benign. Then, we assessed if a subset of these VUSs could be reclassified to LP based on their enrichment in Egyptian patients (ACMG/AMP PS4 rule) or whether they reside in a previously defined mutational hotspot region that has been reported to be enriched for HCM-associated variation (modified 413 ACMG/AMP PM1 rule) $13,32$.

 Our analysis showed that 1 VUS (*MYBPC3* c.305C>T [p.Pro102Leu]) was observed in two Egyptian controls and thus could be reclassified to likely benign according to the ACMG/AMP 417 rules BS1 and BP4 29 . It is worth mentioning that here variant rarity was defined using gnomAD, which lacks sufficient data from MENA populations. Given that variant frequencies may differ across diverse ancestral populations, it is not unexpected to observe "rare" variants in gnomAD to be more prevalent in Egypt (more details in Supplementary Figure 1).

 We then adopted the modified ACMG/AMP PS4 rule proposed by ClinGen, whereby variants prevalent among at least 2, 6 or 15 patients could activate the PS4- supporting, moderate and 424 strong rules, respectively . The PS4 evidence strength levels associated with these specific patient counts were based on likelihood ratios with ideal target thresholds set by ClinGen of 426 10 (PS4-supporting), 30 (moderate) and 100 (strong), respectively . Of all rare variants identified in Egypt HCM patients, irrespective of variant classification, 48,3 and 1 distinct variant(s) were recurrently found in n>=2, n>=6 and n>=15 patients, respectively. Application

 of the modified PS4 rule upgraded the classification of 6/104 VUSs to LP (5.8%) and 10/30 LP variants to P (33.3%).

 We previously identified specific regions in sarcomeric genes in which rare non-truncating variants were significantly enriched in >6,000 HCM patients of predominantly European-434 ancestry (LMM/OMGL) compared to controls $2¹$. For variants residing in these case-enriched clusters, the etiological fraction (EF) was calculated as it provides a quantitative estimate of the probability that a rare non-truncating variant identified in an individual with HCM is disease- causing. Based on the EF findings, the authors proposed an adaptation to the ACMG/AMP guidelines whereby rare variants located in an HCM cluster with an EF>0.95 could activate the PM1 hotspot rule at a modified strong evidence level (leading to the re-classification of VUS to LP).

 As the relative case-control frequencies can differ across population groups, similar enrichment needs to be demonstrated in the population of interest before adopting these modified guidelines. Given the abundance of rare non-truncating variants observed in *MYH7* in the Egypt HCM cohort, we sought to validate the EF-based PM1 ACMG/AMP rule for *MYH7* variants (there were insufficient variants to accurately assess clustering in the troponin genes). First, we examined whether the distribution and enrichment of *MYH7* non-truncating variants was similar between the Egypt and the LMM/OMGL (n=6,112) HCM datasets. As depicted in Figure 4A, a similar distribution of rare missense *MYH7* variants was observed between Egyptian and LMM/OMGL HCM patients, with rare variants in the pre-defined HCM cluster (residues 167-931) significantly enriched in the Egypt HCM cohort over Egypt controls 452 (13.04% vs. 0.25%, p-value=2.2x10⁻¹⁶). As the EF for Egyptian variants within the pre-defined HCM cluster was 1.0 (95%CI: 0.93-1.0), we applied the EF-based PM1_strong ACMG/AMP on rare Egyptian *MYH7* missense variants, irrespective of prior variant classification. A total of 48 missense *MYH7* variants were identified in the Egypt HCM cohort (Supplementary Table 456 2). Application of the EF-based PM1 strong rule upgraded the classification of 23 VUSs to LP

and three LP variants to P, which increased the overall proportion of clinically actionable (i.e.

P/LP) distinct *MYH7* missense variants from 35.4% to 83.3%.

 Taken together, applying the above-mentioned approaches to variant interpretation increased the overall proportion of Egypt HCM patients with clinically actionable variants from 19% to 33.4% (relative increase from 40.8% to 60.4% in the patient subgroup with rare variants in validated HCM genes) (Figure 4B).

466
467

 Figure 4: A) Similar enrichment of rare, missense *MYH7* **variants between the Egypt- and large- scale HCM cohort of predominantly European ancestry (LMM/OMGL n=6,112) in the predefined HCM cluster (red) (residues 167-931).** Rare variants in the HCM cluster were enriched in the Egypt HCM cohort over Egypt controls with an Etiological Fraction (EF) of 1.0. **B) Application of ClinGen's modified ACMG/AMP PS4 rule and Walsh** *et al.,* **2019 proposed EF-based PM1 strong rules in the Egyptian case-control cohort increases the proportion of Egypt HCM patients with clinically actionable variants from 19% to 33.4%.** Rare variants were initially classified based on the ACMG/AMP guidelines (initial analysis) and then reclassified after integrating ancestry-matched controls into the analysis (cohort-informed analysis) and adopting Egypt-specific PS4 and the modified EF-based PM1 strong rules. Cohort-informed analysis revealed that *MYBPC3* p.Pro102Leu was prevalent in the Egypt control cohort (MAF=0.0025) and thus was reclassified from VUS (in case-level 478 analysis) to likely benign (LB, activated ACMG/AMP rules: BS1&BP4). P: pathogenic, LP: likely 479 pathogenic, VUS: variant of uncertain significance. pathogenic, VUS: variant of uncertain significance.

-
-

Enrichment of non-rare variants in Egypt HCM patients

 A growing body of evidence suggests that low frequency variants could contribute to disease \cdot risk with intermediate effects 33 . These variants can be identified through burden tests showing an enrichment in patients followed by functional analyses to investigate their effect on the 486 disease phenotype. Therefore, we sought to assess if low-frequency variants (i.e. 4×10^{-5} $<$ 487 gnomAD FAF_{popmax} < 0.01) were enriched in the Egypt HCM cohort compared to Egypt controls. A total of 20 non-rare protein-altering variants in validated HCM genes were observed in more than one patient in the Egypt HCM cohort (Supplementary Table 10). Of these, *MYBPC3* c.1321G>A [p.Glu441Lys] and *TNNT2* c.832C>T [p.Arg278Cys] were nominally enriched in Egyptian patients over controls (4.67% vs. 2%, p-value=0.03, OR=2.4 (95%CI: 1.0-6.2) and 1.17% vs. 0%, p-value=0.04, OR=10.2 (95%CI: 0.6-182.3), respectively) (although not statistically significant after multiple testing correction). While p.Arg278Cys is enriched in HCM in both Egyptian and European-ancestry cohorts, including the analyzed UK cohort, p.Glu441Lys is infrequently observed in most European HCM cohorts (Supplementary 496 Table 11) $34-37$. This suggests that this variant could be more relevant to Middle Eastern populations. Several publications reported the frequent co-occurrence of these variants with 498 other sarcomeric variants suggesting that they may act as disease modifiers^{33,38–41}. Notably, 37.5% (n=9/24) and 33.3% (n=2) of Egyptian patients with p.Glu441Lys and p.Arg278Cys, respectively, carried another rare sarcomeric variant, including two patients who carried p.Glu441Lys in homozygosity (Supplementary Table 11).

Higher prevalence of *TRIM63* **biallelic variants in the Egypt HCM cohort compared to Europeans**

 Salazar-Mendiguchía *et al.,* 2020 have recently proposed that *TRIM63* is a recessive HCM gene associated with concentric LVH and a high rate of LV dysfunction following the identification of homozygous or compound heterozygous variants in 0.4% of a predominantly 508 European (>90%) HCM cohort . We identified seven homozygous and one compound heterozygous *TRIM63* variants in the Egypt HCM cohort (total=8/374, 2.14%) (Supplementary

 Table 9). No biallelic *TRIM63* variants were identified in the Egypt control cohort. Similar to the recent study, c.224G>A [p.Cys75Tyr] (1.34%) and c.739C>T [p.Gln247Ter] (0.53%) (both homozygous) were the most frequently identified *TRIM63* biallelic variants in the Egypt HCM 513 cohort⁴². The missense variant Cys75Tyr was observed in heterozygosity in 0.5% (2/400) of the Egypt control cohort and in two individuals from the North African sub-populations from the GME study (in hetero- and homozygosity), which indicates that this variant could be 516 particularly prevalent in North African/MENA populations⁴³. A markedly higher frequency of biallelic *TRIM63* variants was observed in the Egypt HCM cohort compared to both the analyzed UK HCM cohort and the recently published European-ancestry enriched cohort 519 (2.14%% vs 0.16%, p-value=0.0019 and vs. 0.4%, p-value=5.8x10⁻⁵, respectively)⁴².

Discussion

 This study represents the largest and most comprehensive analysis of HCM in the MENA region to date. Here, we report the results of genetic analysis of 514 unrelated Egyptian HCM patients and 400 ancestry-matched controls. We show that cohort-level analysis of rare variation in the hitherto understudied Egyptian population provides accurate interpretation of variants rarely observed in published HCM patient groups. In addition, we demonstrate that studying consanguineous populations allows for distinguishing between the relative pathogenicity and penetrance of disease-causing genes.

 First, we show that the proportion of patients with rare variants in validated HCM genes was higher in the Egypt HCM cohort compared to UK HCM (52.7% vs. 32.0%). Recent data from ShaRe registry demonstrated that patients carrying sarcomere variants presented with HCM 533 at an earlier age and had a worse prognosis . Here, Egyptian patients presented with a higher yield of sarcomeric variants compared to the UK HCM cohort (44.8% vs. 29.5%).

 Patients analyzed here were admitted to AHC, which is a tertiary referral center. Thus, they typically presented with severe clinical manifestations at admission. This may explain the markedly younger age of onset (by ca. 20 years) and more severe LVH observed in the Egypt HCM cohort compared to UK HCM. To account for a possible referral bias, we compared the proportion of genotype positive patients attributable to each gene between the Egypt and UK HCM cohorts.

 MYBPC3 and *MYH7* accounted for the majority of rare variation, as with all HCM cohorts. However, some key differences are observed between the Egypt HCM and UK HCM cohorts. For example, we have recently reported the identification of a new class of pathogenic variants in HCM; a nonsense mediated decay-incompetent frameshift variant (c.5769delG) in *MYH7*, which was recurrently observed in Egyptian patients (3.3%) and absent from large-scale 548 (n>6,000) HCM patients of predominantly European ancestry $16,18$. Also, the Egypt HCM data shows an enrichment of *JPH2* missense variants (5.2% Egypt HCM vs. 1.4% UK HCM 550 genotype-positive patients) which rarely cause HCM outside of founder populations. This is 551 largely explained by two recurrent variants that have not been previously reported . One of these variants, p.Thr161Ala, occurs at the same position as another pathogenic variant 553 (p.Thr161Lys) recently reported to be a founder in the Finnish population . This may denote a particular pathogenic hotspot in *JPH2* although further segregation and/or functional data are required to enable a more accurate classification of these variants.

 The main unique finding, however, relates to the clear prevalence of HCM minor genes, particularly *MYL2*, *MYL3* (MLC) and *CSRP3*, in the Egyptian population and the enrichment of homozygous variants in these genes. A noticeably higher proportion of rare variants in MLC genes was observed in the genotype-positive Egypt HCM cohort compared to UK HCM (10.33% vs. 2.28%), including five recurrent variants that were absent from the latter cohort. Interestingly, a substantial proportion of MLC variants (25.6%) were observed in the homozygous state, suggesting such variants are less penetrant in heterozygosity. In

 agreement with this notion, a study by Claes *et al.,* 2016 demonstrated that the expression of the Dutch founder *MYL2* missense variant p.Glu22Lys in isolation was associated with low HCM penetrance and a benign disease manifestation and that the presence of an additional risk factor, including hypertension, obesity or the co-occurrence of another sarcomeric variant, 568 increased the disease penetrance from 36% to 89% in MYL2-variant carriers ⁴⁵. In addition, the authors reported that patients carrying p.Glu22Lys in homozygosity were diagnosed with 570 end-stage heart failure due to HCM in their $30s^{45}$. It is therefore plausible to conclude that the high consanguinity rates observed in the Egypt HCM cohort enabled MLC variants to occur in a more penetrant homozygous state. This may explain, at least in part, the relatively higher proportion of rare MLC variants observed in the analyzed consanguineous Egypt HCM cohort compared to UK HCM. While biallelic truncating variants in *MYL2/MYL3* are associated with severe early onset cardioskeletal myopathies, only two homozygous missense variants 576 in *MYL3* have previously been reported - p.Glu143Lys^{46,47} and p.Ala57Asp^{48,49}. It is noteworthy that the homozygous expression of the non-rare variant p.Ala57Asp, which was 578 observed in HCM patients of Iranian and Tunisian origins born to consanguineous parents^{48,49}. was also observed in the Egypt HCM cohort (in two homozygous and one heterozygous carriers). The homozygous patients presented with HCM at a relatively younger age and had a greater LVWMT (27+2.8mm vs. 16mm) compared to the heterozygous carrier. Although a previous functional study with iPSC-CMs did not demonstrate a phenotype for this variant in 583 either the heterozygous or homozygous state⁵⁰, the fact that is has now been detected as a homozygous variant in four HCM cases (and not detected in our healthy control cohort) suggests it is contributing to the phenotype.

 Similar to MLC-encoding genes, variants in *CSRP3* were more likely to present in homozygosity (33.3%) than the major sarcomere-encoding HCM genes (*MYH7*, *MYBPC3* and thin filament genes, 5-7%). Two of the three homozygous *CSRP3* variants were truncating (c.415-1G>C and c.414+1G>T). These variants were observed in one and three Egyptian patients, respectively. Patients carrying these variants presented with HCM at an average age

 of 45.5+8.7 and a LVMWT of 16.5+2.4mm. It is noteworthy that c.414+1G>T was also observed in heterozygosity in one Egyptian control and HCM patient, respectively. The control did not carry any other rare HCM-associated variant whereas the HCM patient carried the pathogenic *MYH7* c.5769delG variant (and the *JPH2* p.Ser99Asn VUS), suggesting that in the heterozygous state this variant requires an additional mutational burden to express the HCM phenotype. To date, only three knockout *CSRP3* HCM patients have been reported in Poland 598 and France, two of whom were confirmed to be born to consanguineous parents^{51,52}. These patients were diagnosed with adult-onset HCM and one patient underwent Implantable 600 cardioverter defibrillator implantation in her $30s$ $51,52$. Together, these studies suggest that full *CSRP3* gene knockouts, in contrast to the severe early-onset phenotypes observed with biallelic truncating variants in genes like *MYBPC3* and *ALPK3*, are associated with more typical adult-onset HCM, despite the fact that most reports for *CSRP3*-associated HCM involve heterozygous variants and dominant inheritance.

 Taken together, these findings demonstrate that this study is uniquely able to examine the frequency of homozygous variants in dominant HCM genes using a large consanguineous cohort to inform the relative penetrance of variants in these genes. The recurrence of these variants in the Egyptian cohort, which may indeed have generally higher prevalence in other consanguineous populations of the MENA region, exemplifies the need to integrate new guidelines tailored to the classification of homozygous variants into the current ACMG framework in order to enhance the utility of clinical genetic testing in other consanguineous populations.

 The observed high prevalence of consanguinity (28%) in the Egyptian cohort analyzed here has also enabled us to validate recent findings reporting the association of the recessive gene *TRIM63* to HCM⁴². Indeed, the prevalence of biallelic *TRIM63* variants was markedly higher in Egyptian patients compared to HCM patients of European ancestries suggesting that

 recessive inheritance patterns of HCM are more likely to occur in consanguineous populations of the MENA region.

 Our data also highlight the value of performing ancestry-matched case-control analysis coupled with standardized guidelines and quantitative approaches to variant interpretation to 624 accurately classify variants observed in underrepresented populations $13,29,32$. We demonstrate that these approaches enabled 23.1% of distinct VUSs identified in the Egypt HCM cohort to progress to likely pathogenic, enabling a more equitable application of clinical genetic testing in the region. Expanding the MENA dataset in resources like gnomAD will further improve the interpretation of VUSs by providing more accurate frequencies of these variants in the population.

 It is noteworthy that despite the relatively severe phenotypes observed in our cohort, almost 50% of HCM patients in this study presented with an unexplained genetic etiology. This finding is not unexpected as recent evidence suggests that the genetic etiology of HCM is more complex and that common variants with individually small (but collectively large) effect sizes 635 could explain some of the missing heritability of the disease $53,54$. This study is not designed to assess common variants or validate recently described European-ancestry HCM polygenic 637 risk scores $(PRS)^{54}$. However, a recent HCM genome-wide association study (GWAS) identified a common *BAG3* missense variant p.Cys151Arg, as one of the two most strongly associated loci for HCM and which is covered by the targeted gene panel used in this 640 analysis⁵⁴. The OR of p.Cys151Arg was highly similar between the Egyptian cohorts and the published European datasets, 1.47 (95%CI: 1.12-1.95) and 1.42 (95%CI: 1.29-1.55) 642 respectively , although the population frequency for the minor risk allele is lower in Egypt (control MAF=0.12) than Europe (gnomAD-non-Finnish European MAF=0.22). This suggests that there will be likely many shared loci between populations, although well-powered GWAS in MENA populations are warranted to accurately quantify HCM PRS for future clinical use.

 Low frequency variants with effect sizes that are intermediate between common GWAS- derived and rare Mendelian variants are now also emerging as additional genetic risk factors. For example, a recent study by Pua *et al.* identified two low frequency troponin variants (*TNNI3* p.Arg79Cys OR=3.3 (96%CI: 1.5-7.2), MAF=0.018 and *TNNT2* p.Arg286His OR=14.1 (95%CI: 6.0-33.0), MAF=0.022) that are associated with HCM in patients of Chinese ancestry . Similarly, we observed two low frequency variants *MYBPC3* p.Glu441Lys (OR=2.4 (95%CI: 1.0-6.2), MAF=0.025) and *TNNT2* p.Arg278Cys (OR= 10.2 (95%CI: 0.6-182.3), MAF=0.006) that were nominally enriched in the Egyptian HCM cohort. While the *TNNT2* p.Arg278Cys variant is also consistently enriched in European ancestry cohorts, the *MYBPC3* variant p.Glu441Lys is clearly more prevalent in the Egypt HCM cohort, suggesting that it could be 657 more relevant to Egyptian patients $34-37$. In agreement with literature findings, both variants were frequently observed in conjunction with another sarcomeric variant in Egyptian patients, 659 which suggests their modifier effect on the phenotype $38-41$. However, functional studies will be required to definitively ascertain their effect on HCM phenotype.

 A limitation of the study is that the targeted gene panel used does not include genes that have 663 been recently shown to be associated with HCM (*ALPK3*, *FHOD3* and *FLNC*^{56–59}). In addition, the study design did not account for common and copy number variations, non-coding variants or epigenetic factors, which may contribute to HCM pathogenesis. Finally, larger control datasets are needed to fully characterize rare variation in MENA populations.

 In conclusion, we have demonstrated that detailed analysis of rare genetic variation in validated HCM genes in underrepresented populations reveals novel findings with relevance to both clinical genetic testing and our understanding of the genetic etiology of HCM. We report the contribution of minor HCM genes, rarely observed in outbred populations, to disease pathogenicity. We also show a higher prevalence of biallelic variants in the recessive HCM gene *TRIM63* in Egyptian patients suggesting that recessive inheritance of HCM is more likely to occur in consanguineous populations. These unique genetic features exemplify the value

 of studying diverse ancestral populations. The highly consanguineous cohort analyzed here opens new research avenues for the discovery of novel recessive genes in future exome or genome sequencing studies.

Acknowledgements

 We would like to acknowledge Dr. Rafik Tadros and Dr. Paloma Jordà for providing us with HCM and control frequency data regarding the recently reported *BAG3* variant p.Cys151Arg. We would like to thank the AHC nursing staff and team members who contributed to the biobanking efforts in frame of the National HCM Registry.

Funding Statement

 This study is part of the Egyptian Collaborative Cardiac Genomics Project. It was supported by the Science and Technology Development Fund government grant (Egypt), the Wellcome Trust (107469/Z/15/Z; 200990/A/16/Z), the Medical Research Council (United Kingdom), the NIHR Royal Brompton Cardiovascular Biomedical Research Unit, the NIHR Imperial College Biomedical Research Center, and a Health Innovation Challenge Fund award from the Wellcome Trust* and Department of Health, United Kingdom (HICF-R6–373)**. Drs Allouba and Halawa were funded by Al Alfi Foundation to support their PhD degrees at Imperial College London and American University in Cairo, respectively. Dr Aguib is supported by Fondation Leducq (11 CVD-01).

 *This research was funded in part by the Wellcome Trust [107469/Z/15/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

 **The views expressed in this work are those of the authors and not necessarily those of the funders.

It is made available under a CC-BY-NC-ND 4.0 International license.

Web resources

OMIM, https://www.omim.org

References

- 1. Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study. *Circulation*, *92*(4), 785–789. https://doi.org/10.1161/01.CIR.92.4.785
- 2. Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New perspectives on the prevalence of hypertrophic cardiomyopathy. In *Journal of the American College of Cardiology* (Vol. 65, Issue 12). https://doi.org/10.1016/j.jacc.2015.01.019
- 3. Teare, D. (1958). Asymmetrical hypertrophy of the heart. *British Heart Journal*, *20*(1), 1–8.
- 4. Maron, M. S., & Maron, B. J. (2015). Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. *Circulation*, *132*(4). https://doi.org/10.1161/CIRCULATIONAHA.114.014283
- 5. Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. 720 (2014). Hypertrophic cardiomyopathy: Present and future, with translation into
721 contemporary cardiovascular medicine. In Journal of the American College of contemporary cardiovascular medicine. In *Journal of the American College of Cardiology* (Vol. 64, Issue 1). https://doi.org/10.1016/j.jacc.2014.05.003
- 6. Maron, B. J., Rowin, E. J., Casey, S. A., & Maron, M. S. (2016). How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. *JAMA Cardiology*, *1*(1). https://doi.org/10.1001/jamacardio.2015.0354
- 7. Marian, A. J., & Braunwald, E. (2017). Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circulation Research*, *121*(7), 749–770. https://doi.org/10.1161/CIRCRESAHA.117.311059
- 8. Lu, D. Y., Pozios, I., Haileselassie, B., Ventoulis, I., Liu, H., Sorensen, L. L., Canepa, M., Phillip, S., Roselle Abraham, M., & Abraham, T. P. (2018). Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. *Journal of the American Heart Association*, *7*(5). https://doi.org/10.1161/JAHA.117.006657
- 9. O'Mahony, C., Jichi, F., Ommen, S. R., Christiaans, I., Arbustini, E., Garcia-Pavia, P., Cecchi, F., Olivotto, I., Kitaoka, H., Gotsman, I., et al. (2018). International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). *Circulation*, *137*(10). https://doi.org/10.1161/CIRCULATIONAHA.117.030437
- 10. Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., Cirino, A. L., Fox, J. C., Lakdawala, N. K., Ware, J. S., et al. (2018). Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. *Circulation*, *138*(14), 1387–1398. https://doi.org/10.1161/CIRCULATIONAHA.117.033200
- 11. Elliott, P. (2018). Hypertrophic cardiomyopathy lifelong disease requiring lifelong treatment. In *Circulation* (Vol. 138, Issue 14). https://doi.org/10.1161/CIRCULATIONAHA.118.035932
- 12. Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020). Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER- HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, *396*(10253). https://doi.org/10.1016/S0140-6736(20)31792-X
- 13. Walsh, R., Mazzarotto, F., Whiffin, N., Buchan, R., Midwinter, W., Wilk, A., Li, N., Felkin, L., Ingold, N., Govind, R., et al. (2019). Quantitative approaches to variant

753 classification increase the yield and precision of genetic testing in Mendelian diseases :
754 the case of hypertrophic cardiomyopathy. Genome Medicine. 11(5). 1–18. the case of hypertrophic cardiomyopathy. *Genome Medicine*, *11*(5), 1–18. 14. Dellefave-Castillo, L. M., Cirino, A. L., Callis, T. E., Esplin, E. D., Garcia, J., Hatchell,

 K. E., Johnson, B., Morales, A., Regalado, E., Rojahn, S., et al. (2022). Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing. *JAMA Cardiology*. https://doi.org/10.1001/jamacardio.2022.2455

- 15. Landry, L. G., & Rehm, H. L. (2018). Association of racial/ethnic categories with the ability of genetic tests to detect a cause of cardiomyopathy. *JAMA Cardiology*, *3*(4), 341–345. https://doi.org/10.1001/jamacardio.2017.5333
- 16. Aguib, Y., Allouba, M., Walsh, R., Ibrahim, A. M., Halawa, S., Afify, A., Hosny, M., Theotokis, P. I., Galal, A., Elshorbagy, S., et al. (2021). New Variant with a Previously Unrecognized Mechanism of Pathogenicity in Hypertrophic Cardiomyopathy. *Circulation*, *144*(9), 754–757. https://doi.org/10.1161/CIRCULATIONAHA.120.048295
- 17. Aguib, Y., Allouba, M., Afify, A., Halawa, S., El-Khatib, M., Sous, M., Galal, A., Abdelrahman, E., Shehata, N., el Sawy, et al. (2020). The Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project: defining a healthy volunteer cohort. *Npj Genomic Medicine*, *5*(46). https://doi.org/10.1038/s41525-020-00153-w
- 18. Walsh, R., Thomson, K. L., Ware, J. S., Funke, B. H., Woodley, J., McGuire, K. J., Mazzarotto, F., Blair, E., Seller, A., Taylor, J. C., et al. (2017). Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genetics in Medicine*, *19*(2), 192–203. https://doi.org/10.1038/gim.2016.90
- 19. Shawky, R. M., El-Awady, M. Y., Elsayed, .Solaf M., & Hamadan, G. E. (2011). Consanguineous matings among Egyptian population. *The Egyptian Journal of Medical Human Genetics*, *12*, 157–163. https://doi.org/10.1016/j.ejmhg.2011.07.001
- 20. Shawky, R. M., Elsayed, N. S., Ibrahim, D. S., & Seifeldin, N. S. (2012). Profile of genetic disorders prevalent in northeast region of Cairo, Egypt. *Egyptian Journal of Medical Human Genetics*, *13*(1), 45–62. https://doi.org/10.1016/j.ejmhg.2011.10.002
- 21. Walsh, R., Buchan, R., Wilk, A., John, S., Felkin, L. E., Thomson, K. L., Chiaw, T. H., Chin, C., Loong, W., Pua, C. J., et al. (2017). Defining the genetic architecture of 784 hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. *European Society of Cardiology*, *38*, 3461–3468. https://doi.org/10.1093/eurheartj/ehw603
- 22. de Marvao, A., Dawes, T. J. W., Shi, W., Durighel, G., Rueckert, D., Cook, S. A., & O'Regan, D. P. (2015). Precursors of hypertensive heart phenotype develop in healthy adults A High-Resolution 3D MRI Study. *JACC: Cardiovascular Imaging*. https://doi.org/10.1016/j.jcmg.2015.08.007
- 23. Pua, C. J., Bhalshankar, J., Miao, K., Walsh, R., John, S., Lim, S. Q., Chow, K., Buchan, R., Soh, B. Y., Lio, P. M., et al. (2016). Development of a Comprehensive Sequencing Assay for Inherited Cardiac Condition Genes. *Journal of Cardiovascular Translational Research*, *9*(1), 3–11. https://doi.org/10.1007/s12265-016-9673-5
- 24. Ingles, J., Goldstein, J., Thaxton, C., Caleshu, C., Corty, E. W., Crowley, S. B., Dougherty, K., Harrison, S. M., McGlaughon, J., Milko, L. v., et al. (2019). Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circulation: Genomic and Precision Medicine*, *12*(2), 57–64. https://doi.org/10.1161/CIRCGEN.119.002460
- 25. Walsh, R., Offerhaus, J. A., Tadros, R., & Bezzina, C. R. (2021). Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. *Nature Reviews Cardiology*, 1–17. https://doi.org/10.1038/s41569-021-00608-2
- 26. Maron, B. J., Maron, M. S., & Semsarian, C. (2012). Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. In *Journal of the American College of Cardiology* (Vol. 60, Issue 8, pp. 705–715). https://doi.org/10.1016/j.jacc.2012.02.068
- 27. Whiffin, N., Minikel, E., Walsh, R., O/'Donnell-Luria, A. H., Karczewski, K., Ing, A. Y., Barton, P. J. R., Funke, B., Cook, S. A., MacArthur, D., et al. (2017). Using high-

 resolution variant frequencies to empower clinical genome interpretation. *Genetics in Medicine*, *19*(10), 1151–1158. http://dx.doi.org/10.1038/gim.2017.26

- 28. Whiffin, N., Walsh, R., Govind, R., Edwards, M., Ahmad, M., Zhang, X., Tayal, U., Buchan, R., Midwinter, W., Wilk, A. E., et al. (2018). CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. *Genetics in Medicine*, *20*(10), 1246–1254. https://doi.org/10.1038/gim.2017.258
- 29. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*, *17*(5), 405–423. https://doi.org/10.1038/gim.2015.30
- 30. Carrier, L., Mearini, G., Stathopoulou, K., & Cuello, F. (2015). Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. In *Gene* (Vol. 573, Issue 2, pp. 188– 197). https://doi.org/10.1016/j.gene.2015.09.008
- 31. Carrier, L. (2021). Targeting the population for gene therapy with MYBPC3. *Journal of Molecular and Cellular Cardiology*, *150*(September 2020), 101–108. https://doi.org/10.1016/j.yjmcc.2020.10.003
- 32. Kelly, M. A., Caleshu, C., Morales, A., Buchan, J., Wolf, Z., Harrison, S. M., Cook, S., Dillon, M. W., Garcia, J., Haverfield, E., et al. (2018). Adaptation and validation of the ACMG / AMP variant classification framework for MYH7 -associated inherited 829 cardiomyopathies : recommendations by ClinGen 's Inherited Cardiomyopathy Expert Panel. *Genetics in Medicine : Official Journal of the American College of Medical Genetics*, *20*(3), 351–359. https://doi.org/10.1038/gim.2017.218
- 33. Walsh, R., Tadros, R., & Bezzina, C. R. (2020). When genetic burden reaches threshold. *European Heart Journal*, *41*(39). https://doi.org/10.1093/eurheartj/ehaa269
- 34. Mazzarotto, F., Girolami, F., Boschi, B., Barlocco, F., Tomberli, A., Baldini, K., Coppini, R., Tanini, I., Bardi, S., Contini, E., et al. (2019). Defining the diagnostic effectiveness 836 of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. *Genetics in Medicine*, *21*(2). https://doi.org/10.1038/s41436-018-0046-0
- 35. Janin, A., Januel, L., Cazeneuve, C., Delinière, A., Chevalier, P., & Millat, G. (2021). Molecular Diagnosis of Inherited Cardiac Diseases in the Era of Next-Generation Sequencing: A Single Center's Experience Over 5 Years. *Molecular Diagnosis and Therapy*, *25*(3). https://doi.org/10.1007/s40291-021-00530-w
- 36. Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., et al. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. *Genetics in Medicine : Official Journal of the American College of Medical Genetics*, *17*(11), 880–888. https://doi.org/10.1038/gim.2014.205
- 37. Lopes, L. R., Rahman, M. S., & Elliott, P. M. (2013). A systematic review and meta- analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. *Heart*, *99*(24), 1800–1811. https://doi.org/10.1136/heartjnl-2013-303939
- 38. Olivotto, I., Girolami, F., Ackerman, M. J., Nistri, S., Bos, J. M., Zachara, E., Ommen, S. R., Theis, J. L., Vaubel, R. A., Re, F., et al. (2008). Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clinic Proceedings*, *83*(6), 630–638. https://doi.org/10.4065/83.6.630
- 39. Millat, G., Bouvagnet, P., Chevalier, P., Dauphin, C., Simon Jouk, P., da Costa, A., Prieur, F., Bresson, J. L., Faivre, L., Eicher, J. C., et al. (2010). Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. *European Journal of Medical Genetics*, *53*(5), 261–267. https://doi.org/10.1016/j.ejmg.2010.07.007

- 40. Ripoll-Vera, T., Gámez, J. M., Govea, N., Gómez, Y., Núñez, J., Socías, L., Escandell, Á., & Rosell, J. (2016). Clinical and Prognostic Profiles of Cardiomyopathies Caused by Mutations in the Troponin T Gene. *Revista Española de Cardiología (English Edition)*, *69*(2). https://doi.org/10.1016/j.rec.2015.06.025
- 41. Gimeno, J. R., Monserrat, L., Pérez-Sánchez, I., Marín, F., Caballero, L., Hermida- Prieto, M., Castro, A., & Valdés, M. (2009). Hypertrophic Cardiomyopathy. A Study of the Troponin-T Gene in 127 Spanish Families. *Revista Española de Cardiología (English Edition)*, *62*(12). https://doi.org/10.1016/s1885-5857(09)73545-5
- 870 42. Salazar-Mendiguchiá, J., Ochoa, J. P., Palomino-Doza, J., Domínguez, F., Diéz- López, C., Akhtar, M., Ramiro-León, S., Clemente, M. M., Pérez-Cejas, A., Robledo, M., et al. (2020). Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy. *Heart*, *106*(17). https://doi.org/10.1136/heartjnl-2020- 316913
- 43. Scott, E. M., Halees, A., Itan, Y., Spencer, E. G., He, Y., Azab, M. A., Gabriel, S. B., Belkadi, A., Boisson, B., Abel, L., et al. (2016). Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. *Nature Genetics*, *48*(9), 1071–1076. https://doi.org/10.1038/ng.3592
- 44. Vanninen, S. U. M., Leivo, K., Seppälä, E. H., Aalto-Setälä, K., Pitkänen, O., Suursalmi, P., Annala, A. P., Anttila, I., Alastalo, T. P., Myllykangas, S., et al. (2018). Heterozygous junctophilin-2 (JPH2) p. (Thr161Lys) is a monogenic cause for HCM with heart failure. *PLoS ONE*, *13*(9). https://doi.org/10.1371/journal.pone.0203422
- 45. Claes, G. R. F., van Tienen, F. H. J., Lindsey, P., Krapels, I. P. C., Helderman-Van Den Enden, A. T. J. M., Hoos, M. B., Barrois, Y. E. G., Janssen, J. W. H., Paulussen, 885 A. D. C., Sels, J. W. E. M., et al. (2016). Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. *European Heart Journal*, *37*(23). https://doi.org/10.1093/eurheartj/ehv522
- 46. Olson, T. M., Karst, M. L., Whitby, F. G., & Driscoll, D. J. (2002). Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. *Circulation*, *105*(20). https://doi.org/10.1161/01.CIR.0000018444.47798.94
- 47. Caleshu, C., Sakhuja, R., Nussbaum, R. L., Schiller, N. B., Ursell, P. C., Eng, C., de Marco, T., Mcglothlin, D., Burchard, E. G., & Rame, J. E. (2011). Furthering the link between the sarcomere and primary cardiomyopathies: Restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy. *American Journal of Medical Genetics, Part A*, *155*(9). https://doi.org/10.1002/ajmg.a.34097
- 48. Osborn, D. P. S., Emrahi, L., Clayton, J., Tabrizi, M. T., Wan, A. Y. B., Maroofian, R., Yazdchi, M., Garcia, M. L. E., Galehdari, H., Hesse, C., et al. (2021). Autosomal recessive cardiomyopathy and sudden cardiac death associated with variants in MYL3. *Genetics in Medicine*, *23*(4), 787–792. https://doi.org/10.1038/s41436-020- 01028-2
- 49. Jaafar, N., Gómez, J., Kammoun, I., Zairi, I., Amara, W. ben, Kachboura, S., Kraiem, S., Hammami, M., Iglesias, S., Alonso, B., & Coto, E. (2016). Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes among Tunisian Patients. *Genetic Testing and Molecular Biomarkers*, *20*(11), 674–679. https://doi.org/10.1089/gtmb.2016.0187
- 50. Ma, N., Zhang, J. Z., Itzhaki, I., Zhang, S. L., Chen, H., Haddad, F., Kitani, T., Wilson, K. D., Tian, L., Shrestha, R., et al. (2018). Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent stem cells. *Circulation*, *138*(23). https://doi.org/10.1161/CIRCULATIONAHA.117.032273
- 51. Janin, A., Bessière, F., Chauveau, S., Chevalier, P., & Millat, G. (2018). First identification of homozygous truncating CSRP3 variants in two unrelated cases with hypertrophic cardiomyopathy. *Gene*, *676*, 110–116. https://doi.org/10.1016/j.gene.2018.07.036

- 52. Lipari, M., Wypasek, E., Karpinski, M., Tomkiewicz-Pajak, L., Laino, L., Binni, F., Giannarelli, D., Rubis, P., Petkow-Dimitrow, P., Undas, A., et al. (2020). Identification of a variant hotspot in MYBPC3 and of a novel CSRP3 autosomal recessive alteration in a cohort of Polish cases affected by hypertrophic cardiomyopathy. *Polish Archives of Internal Medicine*. https://doi.org/10.20452/pamw.15130
- 53. Harper, A. R., Goel, A., Grace, C., Thomson, K. L., Petersen, S. E., Xu, X., Waring, A., Ormondroyd, E., Kramer, C. M., Ho, C. Y., et al. (2021). Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. *Nature Genetics*, *53*(2). https://doi.org/10.1038/s41588-020-00764-0
- 54. Tadros, R., Francis, C., Xu, X., Vermeer, A. M. C., Harper, A. R., Huurman, R., Kelu Bisabu, K., Walsh, R., Hoorntje, E. T., et al. (2021). Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, *53*(2). https://doi.org/10.1038/s41588-020-00762-2
- 55. Pua, C. J. B., Tham, N., Chin, C. W. L., Walsh, R., Khor, C. C., Toepfer, C. N., Repetti, G. G., Garfinkel, A. C., Ewoldt, J. F., Cloonan, P., et al. (2020). Genetic studies of hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2 that are common in Chinese patients. *Circulation: Genomic and Precision Medicine*. https://doi.org/10.1161/CIRCGEN.119.002823
- 56. Wooten, E. C., Hebl, V. B., Wolf, M. J., Sarah, R., Orr, N., Draper, I., Calvino, J. E., Navin, K., Maron, M. S., Kullo, I. J., et al. (2013). Formin Homology 2 Domain Containing 3 (FHOD3) Variants Associated with Hypertrophic Cardiomyopathy. *Circulation Cardiovascular Genetics*, *6*(1), 10–18. https://doi.org/10.1161/CIRCGENETICS.112.965277.Formin
- 57. Gómez, J., Lorca, R., Reguero, J. R., Morís, C., Martín, M., Tranche, S., Alonso, B., 940 Iglesias, S., Alvarez, V., Díaz-Molina, B., et al. (2017). Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients. *Circulation: Cardiovascular Genetics*, *10*(2). https://doi.org/10.1161/CIRCGENETICS.116.001584
- 58. Valdés-Mas, R., Gutiérrez-Fernández, A., Gómez, J., Coto, E., Astudillo, A., Puente, D. A., Reguero, J. R., Álvarez, V., Morís, C., León, D., Martín, M., et al. (2014). Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy. *Nature Communications*, *5*. https://doi.org/10.1038/ncomms6326
- 59. Almomani, R., Verhagen, J. M. A., Herkert, J. C., Brosens, E., van Spaendonck- Zwarts, K. Y., Asimaki, A., van der Zwaag, P. A., Frohn-Mulder, I. M. E., Bertoli-Avella, 949 A. M., Boven, L. G., et al. (2016). Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy. *Journal of the American College of Cardiology*, *67*(5), 515–525. https://doi.org/10.1016/j.jacc.2015.10.093
-